Wiemels Joseph L, Wiencke John K, Patoka Joseph, Moghadassi Michelle, Chew Terri, McMillan Alex, Miike Rei, Barger Geoffrey, Wrensch Margaret
Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94143-0560, USA.
Cancer Res. 2004 Nov 15;64(22):8468-73. doi: 10.1158/0008-5472.CAN-04-1706.
We and others have reported previously that adults with glioma are 1.5- to 4-fold less likely than controls to report a variety of allergic conditions. The consistent nature of this relationship calls for a biological explanation so that preventative or therapeutic modalities can be explored. We enrolled 403 newly diagnosed adult glioma cases in the San Francisco Bay Area over a 3-year period using a population-based cancer registry and 402 age/gender/ethnicity frequency-matched controls identified via random digit dialing. We assessed total, food-specific, and respiratory-specific IgE in available case (n = 228) and control (n = 289) serum samples. IgE levels were associated with gender, age, smoking status, and ethnicity among cases and/or controls. Among the cases, IgE levels were not associated with aspects of glioma therapy including radiation, chemotherapy, or tumor resection. Total IgE levels were lower in cases than controls: age/gender/ethnicity/education/smoking-adjusted odds ratio (OR) for elevated versus normal total IgE was 0.37 [95% confidence interval (CI), 0.22-0.64]. For the food panel, OR was 0.12 (95% CI, 0.04-0.41). For the respiratory panel, OR was 0.76 (95% CI, 0.52-1.1). Among respiratory allergies, late age of onset (>12 years) but not IgE levels defined a group with strong associations with risk (OR, 0.50; 95% CI, 0.33-0.75). These results corroborate and strengthen our findings of an inverse association between allergic reactions and glioma by showing a relationship with a biomarker for allergy and cancer for the first time. Furthermore, the results indicate a complex relationship between allergic disease and glioma risk that varies by allergen and allergic pathology.
我们和其他研究人员之前曾报告称，患有胶质瘤的成年人报告各种过敏症状的可能性比对照组低1.5至4倍。这种关系的一致性需要生物学解释，以便探索预防或治疗方法。我们在3年时间里，通过基于人群的癌症登记系统，招募了旧金山湾区403例新诊断的成年胶质瘤病例，并通过随机数字拨号确定了402例年龄、性别、种族频率匹配的对照。我们评估了现有病例（n = 228）和对照（n = 289）血清样本中的总IgE、食物特异性IgE和呼吸道特异性IgE。在病例和/或对照中，IgE水平与性别、年龄、吸烟状况和种族有关。在病例中，IgE水平与胶质瘤治疗的各个方面无关，包括放疗、化疗或肿瘤切除。病例组的总IgE水平低于对照组：总IgE升高与正常的年龄/性别/种族/教育/吸烟调整后的优势比（OR）为0.37 [95%置信区间（CI），0.22 - 0.64]。对于食物组，OR为0.12（95% CI，0.04 - 0.41）。对于呼吸道组，OR为0.76（95% CI，0.52 - 1.1）。在呼吸道过敏中，发病较晚（>12岁）而非IgE水平定义了一个与风险有强烈关联（OR，0.50；95% CI，0.33 - 0.75）的组。这些结果首次通过显示与过敏和癌症的生物标志物之间的关系，证实并加强了我们关于过敏反应与胶质瘤之间存在负相关的发现。此外，结果表明过敏疾病与胶质瘤风险之间存在复杂关系，这种关系因过敏原和过敏病理而异。
